Journal
JOURNAL OF SURGICAL ONCOLOGY
Volume 124, Issue 8, Pages 1477-1484Publisher
WILEY
DOI: 10.1002/jso.26635
Keywords
sarcoma; lung metastasis; metastasectomy; risk score
Funding
- NCATS NIH HHS [TL1 TR002382, UL1 TR002378] Funding Source: Medline
Ask authors/readers for more resources
Surgical resection for sarcoma lung metastases is associated with improved overall survival. Patients with certain characteristics, such as older age, retroperitoneal primary tumor, R1 resection of primary tumor, and multiple lung metastases, have decreased overall survival. A risk score was developed to stratify patients into low-risk and high-risk groups, with significantly better 5-year overall survival in low-risk patients. This risk score may be an important tool for preoperative counseling and consideration for multimodal therapy.
Background Surgical resection for sarcoma lung metastases has been associated with improved overall survival (OS). Methods Patients who underwent curative-intent resection of sarcoma lung metastases (2000-2016) were identified from the US Sarcoma Collaborative. Patients with extrapulmonary metastatic disease or R2 resections of primary tumor or metastases were excluded. Primary endpoint was OS. Results Three hundred and fifty-two patients met inclusion criteria. Location of primary tumor was truncal/extremity in 85% (n = 270) and retroperitoneal in 15% (n = 49). Forty-nine percent (n = 171) of patients had solitary and 51% (n = 180) had multiple lung metastasis. Median OS was 49 months; 5-year OS 42%. Age >= 55 (HR 1.77), retroperitoneal primary (HR 1.67), R1 resection of primary (HR 1.72), and multiple (>= 2) lung metastases (HR 1.77) were associated with decreased OS(all p < 0.05). Assigning one point for each factor, we developed a risk score from 0 to 4. Patients were then divided into two risk groups: low (0-1 factor) and high (2-4 factors). The low-risk group (n = 159) had significantly better 5-year OS compared to the high-risk group (n = 108) (51% vs. 16%, p < 0.001). Conclusion We identified four characteristics that in aggregate portend a worse OS and created a novel prognostic risk score for patients with sarcoma lung metastases. Given that patients in the high-risk group have a projected OS of <20% at 5 years, this risk score, after external validation, will be an important tool to aid in preoperative counseling and consideration for multimodal therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available